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Fabrication of hydrophobic drug nanoparticles using a microfluidic spray 
dryer 
Julian Thiele,a,b Adam R. Abate,a Maike Windbergs,a Ho Cheung Shum,a Stephan Förster,b and David A. Weitza‡ 
 
We present a technique for fabricating hydrophobic drug 
nanoparticles using a microfluidic spray dryer. The 
nanoparticles are formed by evaporative precipitation of 
the spray in air at room temperature. Using danazol as a 
model drug, amorphous nanoparticles are yielded with 
narrow size distribution, 20-60 nm in diameter. As the 
device geometry allows us to inject two separate solvent 
streams, the production of drug co-precipitates with 
tailor-made composition for optimization of therapeutic 
efficiency is greatly facilitated. 
 
Introduction 
The molecular complexity of drugs has significantly 
increased over the last decade.[1][2][3] Although molecular 
complexity usually contributes to biological activity, it often 
causes poor solubility of drugs.[2][4] This limits their 
bioavailability and release in the human body, restricting 
application and commercialization of potential 
candidates.[5][6] A major approach to increase the 
bioavailability of a drug is reducing the particle size, which 
increases the specific surface and, therefore, facilitates 
release and absorption of the drug.[7][8][9][10] 
 In this context, spray drying is a powerful technique 
enabling instantaneous drying of solutions, emulsions or 
suspensions in one step. The final product is a fine powder 
with a large surface area. The pharmaceutical application of 
spray drying techniques covers a broad field ranging from 
manufacturing dry plant extracts avoiding decomposition of 
thermo-sensitive components, to the production of excipients 
for compression with improved binding characteristics. 
[11][12][13] However, conventional spray dryers often 
induce high production costs as the fabrication process 
involves high pressure and complex experimental setups. In 
addition, particle sizes below 100 nm, as often required for 
targeted drug delivery, are usually not achievable with 
commercially available spray dryers.[14][15] These 
limitations can be overcome using 
microfluidics.[16][17][18][19][20] A convenient technique to 
fabricate rather sophisticated microfluidic devices is soft 
lithography using poly(dimethylsiloxane) 
(PDMS).[21][22][23] Unfortunately however, hydrophobic 
compounds easily adsorb onto PDMS microchannels and foul 
the device.[24][25] An optimal system for fabricating 
nanoparticles from hydrophobic drugs would combine the 
versatility of microfluidics with the ability to process 
hydrophobic drugs by spray drying. 
In this paper, we fabricate hydrophobic drug 
nanoparticles using a microfluidic spray dryer. The device 
geometry has a high aspect ratio and is rendered hydrophilic 
by oxygen plasma treatment. This prevents the adsorption of 
hydrophobic precipitates on the channel walls, thus enabling 
the use of hydrophobic drugs in PDMS-based microfluidic 
devices. By controlling the collection distance of the spray, 
we control the crystallinity of the product. Our microfluidic 
device enables fabrication of drug nanoparticles less than 
100 nm in diameter. The versatile device design also enables 
the formation of amorphous co-precipitates by co-spray 
drying the drug with a crystallization inhibitor to improve the 
bioavailability of hydrophobic drugs. 
 
Results and Discussion 
In conventional spray dryers, a single liquid stream is 
typically vaporized by compressed air in a spray nozzle; the 
spray is then mixed with a heated gas stream in a drying 
chamber to evaporate the solvent and yield the dry 
product.[15] However, this setup only allows processing of 
single solvent systems or mixtures of premixed solvents. To 
process multiple separate solvent streams as required for 
solvent/antisolvent precipitation or rapidly reacting solvent 
streams, the spray dryer generally needs to be equipped with 
additional separate inlet channels.[26] In this work, we use a 
microfluidic device with an array of two flow-focusing cross 
junctions, as shown in Figure 1. 
 
Fig. 1 Schematic of a microfluidic device for forming nanoparticles 
from hydrophobic drugs by spray drying. The microfluidic device is 
rendered hydrophilic using oxygen plasma. The device geometry 
enables separate injection of two solvent streams of which the spray 
is formed. 
 
The device enables separate injection of two solvents and 
provides a third inlet for compressed air to form the spray. 
For the formation of hydrophobic drug nanoparticles, we 
dissolve the hydrophobic drug in an organic solvent injected 
into the first inlet, and inject the second fluid into the second 
inlet. The two solvents form a jet at the first cross junction, 
which extends into the second cross junction where 
compressed air is injected to form the spray. To process 
hydrophobic drugs, the PDMS device must resist fouling due 
to adsorption of drug crystals on the microchannel walls. We 
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achieve this by treating the intrinsically hydrophobic PDMS 
device with oxygen plasma, as the plasma renders the spray 
dryer hydrophilic.[27] Although the hydrophilicity of the 
plasma treated device decreases over time, the channel 
surface can easily be regenerated in the same manner 
multiple times. To further improve the resistance against 
fouling, we minimize the surface contact between the drug-
loaded solvent stream and the channel walls. We achieve this 
by designing a device geometry with a high aspect ratio; the 
ratio h/w is 10:1 in the upper half of the device and 4:1 at the 
spray nozzle. As high aspect channels are less pressure-
resistant than square channels, the operating spray dryer 
easily expands, as shown in Figure 2. 
To determine the impact of the channel deformation 
on the flow profile, we process a typical solvent/antisolvent 
system in our spray dryer and compare the device 
deformation at low and high pressure. Our observations are 
supported by computational fluid dynamics (CFD) 
simulations using COMSOL 4.0a. We design a 3D simulation 
model considering the structural mechanics of the PDMS 
channels, the fluid flow described by the Navier-Stokes 
equations and the diffusion of the solvent streams. For the 
spray experiment at low pressure, we inject the solvent 
isopropyl alcohol (IPA), the antisolvent water and 
compressed air into the first, second and third inlet, 
respectively, at flow rates of 1 mL h-1 for the inner phase and 
10 mL h-1 for the middle phase. The air pressure is set to 
0.34 bar, as shown in Figure 2, left. For the high-pressure 
experiment, we increase the flow rates of IPA and water to 
5 mL h-1 and 50 mL h-1, respectively, and set the air pressure 
to 2.09 bar, as shown in Figure 2, right. At low pressure 
(0.34 bar), the PDMS device demonstrates minimal 
deformation and we observe a two dimensional focused flow 
pattern between the first and second cross junction. However, 
as we increase the pressure, the PDMS device responds to the 
internal stress and expands. Due to the high aspect ratio, the 
strongest expansion of the microchannels is observed in 
horizontal direction lateral to the fluid flow; the channel walls 
adapt a quasi-circular shape. This deformation strongly 
influences the flow profile inside the spray dryer, as shown in 
Figure 2, bottom. As illustrated by the simulation of the 
device, the flow profile between the first and second cross 
junction adopts a three dimensional coaxial flow pattern, 
similar to that observed in capillaries.[28] Thereby, the inner 
phase is surrounded by a protective sheath of the middle 
phase. This minimizes the surface contact of the solvent in 
which the hydrophobic drug is dissolved with the channel 
walls and prevents fouling of our spray dryer. 
 
Fig. 2 Pressure-induced deformation of the spray dryer during 
operation. The impact of the deformation on the flow profile is 
studied using CFD simulations. The initial rectangular 
microchannels expand and adopt a quasi-circular shape. This 
deformation changes the flow pattern from a two dimensional 
focused flow to a coaxial flow, therefore reducing the contact 
surface between the drug-loaded solvent stream and the channels 
walls. The scale bars denote 100 µm. 
 
When forming a spray, the spray shape and drop 
size are important factors influencing drying, particle size and 
morphology of the processed drug. To determine drop size 
and spray shape, we visualize the spray formation in our 
spray dryer by recording movies with a high-speed camera. 
We inject IPA into the first and second inlet at a total flow 
rate of 55 mL h-1. At low air pressure, the solvent stream is 
not dispersed into a spray; instead, a jet of liquid is ejected 
from the spray nozzle and breaks into large droplets due to 
Rayleigh-Plateau instability, as shown in Figure 3a.[28] As 
the air pressure is increased beyond 0.5 bar, we observe the 
formation of finely dispersed drops at the spray nozzle, which 
adopt a round full cone spray pattern. This precise pattern is 
formed due to turbulences imparted to the liquid prior to the 
orifice in the short outlet channel. To quantify the spray 
formation process, we measure the drop size d as a function 
of the air pressure p, as shown in Figure 3b. The drop size 
decreases linearly with increasing pressure to approximately 
4 µm in diameter at 2.1 bar, which is the maximum pressure 
our spray dryer can withstand without delamination of the 
plasma-bonded PDMS. However, a higher air pressure is 
easily achievable by increasing the spacing between the 
microchannels and, therefore, the pressure resistance of the 
PDMS device. 
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Fig. 3 (a) Spray profile of the nozzle for different air pressures. IPA 
is injected into the spray dryer at 50 mL h-1. At low pressure, a fluid 
jet is ejected from the nozzle which breaks into single droplets 
downstream. When the pressure is increased beyond 0.5 bar, the 
spray profile adopts full cone spray pattern. The scale bar for all 
panels denotes 100 µm. (b) Drop diameter as a function of p. With 
increasing pressure, the mean size of the droplets decreases linearly. 
At a pressure of 2.1 bar, the droplets are approximately 4 µm in 
diameter. The red line is a guide to the eye. 
 
We demonstrate the concept to form hydrophobic 
drug nanoparticles with our microfluidic spray dryer. We use 
danazol as a model drug, which is an isoxazole derivative of 
testosterone and applied for the treatment of endometriosis 
and hereditary angioedema.[17] A convenient method for 
processing hydrophobic drugs is liquid antisolvent 
precipitation (LASP), where the drug, dissolved in an 
alcohol, is precipitated by mixing the drug solution with 
water as the antisolvent.[11][29] We dissolve danazol in 
isopropyl alcohol and inject it together with water into the 
first cross junction. As we operate our microfluidic device in 
the laminar flow regime, only diffusion based mixing of the 
solvent streams is observed at their interfaces, which does not 
lead to any precipitation of the drug. To evaluate the sole 
effect of microfluidic processing on particle size and 
morphology of the hydrophobic drug, no stabilizer or 
surfactant is added to influence the particle growth. We set 
the flow rates to 5 mL h-1 for danazol, and 50 mL h-1 for 
water, which corresponds to a volumetric ratio of 1:10 and 
has been shown to yield danazol microparticles in 
conventional LASP processes.[17] The spray is completely 
suspended in air, thus ensuring that the product is dried upon 
collection. We examine the morphology and particle size of 
the processed drug by scanning electron microscopy (SEM) 
analysis. While unprocessed (raw) danazol is composed of 
particles with irregular shapes ranging from approximately 
2 µm to 100 µm, we decrease the particle size significantly 
by processing the drug using our microfluidic spray dryer. As 
shown in Figure 4a, we yield danazol nanoparticles with 
narrow particle size distribution (PSD) from 20 nm to 60 nm 
and, therefore, smaller than previously reported.[3][17] 
 
 
Fig. 4 Effect of the solvent system on particle size and composition. 
Danazol in IPA is mixed with (a) water as the antisolvent, or (b) IPA 
as the solvent inside the microfluidic spray dryer. In either cases, 
nanoparticles are yielded with narrow PSD, 20-60 nm in diameter. 
Scale bars denote 300 nm. 
 
The formation of drug nanoparticles using LASP is 
driven by mixing of the drug solution with the antisolvent. 
Thereby, the degree of supersaturation of the drug solution 
governs nucleation and growth of the drug nanoparticles.[11] 
However, sufficient mixing only occurs in the short outlet 
channel prior to the orifice of the spray nozzle in our 
microfluidic device. As we use high flow rates to form a 
stable spray, the delay time of the fluids in the outlet channel 
should be too short to enable growth of nuclei by mixing. To 
reveal the formation process, we substitute the antisolvent by 
the solvent. We inject a solution of danazol in IPA and pure 
IPA into the first and second inlet, respectively. The 
formation of danazol nanoparticles of identical size and 
morphology in the absence of the antisolvent indicates that 
the particle formation is primarily driven by the evaporation 
of the spray and not by the formation of nuclei due to 
supersaturation, as shown in Figure 4b. 
Another crucial aspect of the spray drying process is 
the collection distance of the final product. While it is known 
that the morphology and size of hydrophobic drugs is 
dependent on the initial concentration of reactants, the choice 
of additives and the ratio of solvent and antisolvent,[30] we 
find a significant dependence on the collection distance by 
performing spatial sampling of the spray. To illustrate this, 
we inject danazol together with IPA as previously, but this 
time we collect the spray in steps of 5 cm from the spray 
nozzle. SEM analysis is performed revealing two distinct 
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product morphologies. At a collection distance of 5 cm, we 
observe a layer-by-layer assembly of danazol; the thickness 
of each layer is 60 nm to 80 nm, as shown in Figure 5a. 
These values are in good approximation with the size of 
single danazol nanoparticles, as shown in Figure 4a and 4b.  
 
Fig. 5 Spatial sampling of processed danazol. Depending on the 
collection distance, various morphologies are observed; (a) layer-by-
layer assembly, each 60 nm to 80 nm in thickness, and (b) 
nanoparticles, approximately 20 nm to 60 nm in diameter, 
assembled in a dense network. (c) XRPD patterns of processed 
danazol collected at a distance of 5 cm and 30 cm from the spray 
nozzle, and unprocessed (raw) danazol as a reference. 
 
However, as the time of flight is too short to allow 
for complete evaporation of the spray upon collection, the 
remaining solvent increases the mobility of particles on the 
collection substrate, allowing them to fuse and reach an 
energetically more favorable state.[11] We therefore increase 
the collection distance to 30 cm; as the spray is completely 
evaporated, single nanoparticles are formed, as shown in 
Figure 5b. X-ray powder diffraction analysis (XRPD) is 
employed to determine the effect of spatial sampling on the 
crystallinity of danazol. We use the characteristic peaks at 2θ 
of 15.8, 17.1 and 19.0 in the XRD pattern of unprocessed 
danazol as reference. In processed danazol, the intensity of 
the characteristic peaks decreases as the collection distance of 
the spray is increased. This indicates that the initial 
crystallinity of the drug is not recovered, as shown in Figure 
5c. The formation of amorphous danazol is of importance, as 
the difference in physicochemical properties of the 
amorphous form significantly increases the bioavailability of 
danazol.[17] 
Another way to fabricate amorphous hydrophobic 
drug particles is to co-spray dry the drug and a crystallization 
inhibitor.[31] To demonstrate this using our microfluidic 
spray dryer, we perform two experiments. We co-spray dry 
danazol in IPA together with water and collect the spray at 
low distance. As shown before, the spray is not completely 
evaporated due to the short time of flight. This allows 
danazol to grow into star-shape crystalline aggregates, as 
shown in Figure 6a. However, by using a crystallization 
inhibitor, amorphous danazol is formed. We use 
poly(vinylpyrrolidone) (PVP), which is well known to inhibit 
crystal growth in pharmaceutical 
formulations.[32][33][34][35] We process danazol in IPA 
together with a 1.5 wt% solution of PVP in water at equal 
flow rates of 25 mL h-1, as shown in Figure 6b. Again, the 
spray is collected at short distance. However, as the spray is 
dried, danazol precipitates from the spray in a PVP matrix 
without crystallization, thus no characteristic peaks are 
observed in the XRPD pattern.  
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Fig. 6 Inhibition of danazol crystallization by PVP. (a) Danazol in IPA is mixed with water inside the microfluidic device; the spray is collected at 
a distance of 5 cm from the nozzle, allowing danazol to grow into crystalline aggregates, as indicated by the XRPD pattern. (b) By processing 
danazol in IPA and an aqueous solution of PVP, which are injected separately into our spray dryer, amorphous co-precipitates are yielded, as 
indicated by the XRPD pattern. Scale bars denote 5 m. 
 
To demonstrate the advantages of our microfluidic 
spray dryer, we perform spray drying experiments with the 
same formulations in a conventional laboratory spray dryer 
and compare the results by XRPD and SEM. We use a Mini 
Spray Dryer B 191 (Büchi, Germany) with a spray rate of 
10 mg min-1, and process a solution of danazol in IPA as well 
as a solution of danazol in IPA together with PVP. In the 
former case, we yield particles ranging from approximately 
1 µm to 5 µm, and, therefore, substantially larger than the 
danazol particles formed with our microfluidic spray dryer. 
Moreover, the crystallinity of danazol is retained, as shown in 
Figure 7a. Similar results are observed for the formation of 
co-precipitates of danazol and PVP, as shown in Figure 7b. 
Although the initial crystallinity of danazol is suppressed by 
PVP, the particles are again two orders of magnitude larger 
than in comparable experiments using our microfluidic 
device. 
 
Fig. 7 Fabrication of danazol particles and danazol/PVP co-
precipitates in a conventional spray dryer using the same 
formulations as in our microfluidic device. (a) Instead of amorphous 
drug nanoparticles, crystalline microparticles, and (b) microscopic 
co-precipitates are yielded. 
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Experimental 
Device Fabrication 
The PDMS microfluidic devices are fabricated using soft 
lithography.[21] All channels have a fixed height of 100 µm. 
The PDMS replica is bonded to a flat sheet of cured PDMS 
using oxygen plasma treatment. The plasma treatment 
renders the microchannels temporarily hydrophilic.[27] To 
retain the hydrophilic surface modification, suitable for 
handling hydrophobic drugs, the device is flushed with 
deionized water. The nozzle of the spray dryer is prepared by 
slicing the outlet channel of the stamped device with a razor 
blade. To achieve reproducible accuracy when slicing, we 
include a guide to the eye in the initial AutoCAD design of 
the spray dryer. 
Spray drying experiments 
PVP (weight-averaged molecular weight, MW 10,000 g mol
-1) 
and all other chemicals are obtained from Sigma-Aldrich Co. 
unless noted otherwise. Danazol (99.9 %) is obtained from 
Selectchemie AG. Water with a resistivity of 16.8 MΩcm-1 is 
prepared using a Millipore Milli-Q system. All solutions are 
filtered through a 0.2 µm PTFE filter (Millipore). We form 
danazol nanoparticles using our microfluidic spray dryer. To 
demonstrate long term stability of the process, each 
experiment is performed over a time period of 2 h. We inject 
a saturated solution of danazol in IPA into the first inlet and 
water or IPA into the second inlet at 5 mL h-1 and 50 mL h-1, 
respectively. For the formation of co-precipitates, we inject 
PVP in water (1.5 % w/w) at 50 mL h-1 into the second inlet. 
To form the spray, air is injected into the third inlet at 2.1 bar. 
The spray is ejected into air and dried at room temperature; 
the yield ranges from 70 % to 95 %. We image the spray 
using a Phantom v9.1 camera (Vision Research) at 
64,000 fps. The droplet size is obtained by measuring the size 
of at least 200 drops from high-speed camera images. 
Product collection and characterization 
Processed danazol is collected at distances between 5 cm and 
30 cm from the spray nozzle. For SEM analysis, the spray is 
collected on glass slides and coated with Pd/Pt. We use an 
Ultra55 Field Emission SEM (Zeiss). The size distribution of 
the nanoparticles is determined by image analysis of SEM 
photographs using ImageJ. For XRPD analysis, samples are 
collected in an aluminium box over which the spray dryer is 
mounted. XPRD analysis is performed using a Scintag 
XDS2000 powder diffractometer (Scintag, Cupertino, 
California, USA) with Cu Kα radiation at 40 kV and 30 mA. 
The XRD patterns are taken at room temperature in the range 
of 10° ≤ 2θ ≤ 50° with a scan rate of 1° min-1 and a step size 
of 0.02°. 
 
Conclusions 
Our microfluidic spray dryer allows us to form nanoparticles 
from hydrophobic drugs. As shown for our model drug 
danazol, amorphous nanoparticles are yielded with narrow 
size distribution and lowest reported mean particle size. Due 
to the hydrophilic surface treatment and the high aspect ratio 
of the microchannels, fouling of the microfluidic device is 
prevented. This allows for application of the spray drying 
approach for nanoparticles to a wider range of hydrophobic 
drugs and creates new opportunities for the development of 
commercial formulations of water-insoluble drugs. As the 
spray is dried at room temperature, our microfluidic device 
also enables processing of thermo-sensitive materials. By 
independent injection of two solvent streams, co-precipitates 
of hydrophobic drugs can be prepared. As the two solvent 
streams do not mix before spray formation, our device also 
enables spray drying of rapidly reacting compounds. Our 
approach should also be useful for forming composite 
nanoparticles with freely tunable composition. In addition, 
nanosuspensions, which greatly enhance the dissolution rate 
and bioavailability of hydrophobic drugs, can be easily 
prepared by spraying the nanoparticles into a stabilizer 
solution.[2][11] 
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